News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
INNOVENT BIO (01801.HK) IBI343 NDA for Advanced Gastric Cancer Accepted by NMPA
INNOVENT BIO (01801.HK) announced that the international Phase III clinical study (G-HOPE-001, NCT06238843) of IBI343 for patients with advanced gastric cancer has completed its fi...
Reset
Send
The window will close in 5 seconds
INNOVENT BIO (01801.HK) IBI343 NDA for Advanced Gastric Cancer Accepted by NMPA
Close
Recommend
7
Positive
8
Negative
4
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

INNOVENT BIO (01801.HK)  +0.200 (+0.262%)    Short selling $414.90M; Ratio 35.508%   announced that the international Phase III clinical study (G-HOPE-001, NCT06238843) of IBI343 for patients with advanced gastric cancer has completed its first interim analysis as pre-specified and met the primary endpoint. Based on these positive clinical results, the company has submitted a New Drug Application (NDA) for IBI343 to the National Medical Products Administration of China. The application has been accepted and granted priority review for the treatment of locally advanced unresectable or metastatic CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma in patients who have received at least two prior systemic therapies.

IBI343 is the world’s first CLDN18.2-targeted antibody-drug conjugate (ADC) to have its regulatory application accepted for review. (sl/a)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-05 16:25.)

Related NewsCiti: Market Overreacts to Potential Biopharma Tech Export Restrictions, Creating Buy Opportunities

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.